12 results about "Regulon" patented technology

The present invention relates to lactose-positive, sucrose-negative, Streptococcus thermophilus strains. The strains are carrying one or more mutation in one or more gene of the sucrose regulon and optionally one or more further mutation affecting the glucose porter, such as affecting glcU and / or its expression. The strains of the present invention may further carry mutations in genes encoding a protein of the mannose-glucose-specific PTS and a glucokinase, a protein of the mannose-glucose-specific PTS and the catabolite control protein A (CcpA), and / or a protein of the mannose-glucose-specific PTS, a glucokinase and CcpA. The inventive strains may, when fermenting milk do this without the need or with a need for adding a reduced amount of sucrose, optionally providing a low-lactose fermented milk and / or a fermented milk not undergoing post-acidification when stored at fermentation temperature. The invention also concerns a composition comprising at least one, lactose-positive, sucrose-negative, Streptococcus thermophilus strain of the invention, and the use of this strain or composition to manufacture a fermented dairy product.

The invention relates to the technical field of gene engineering, in particular to a recombinant plasmid, a construction method and application of the recombinant plasmid to improvement of the synthesis capacity of nostoc flagelliforme pseudocladodin. The recombinant plasmid comprises a vector plasmid, and an sgRNA target sequence, an HR homologous sequence, a psbA promoter sequence and an ScyR regulator gene which are connected to the vector plasmid. The recombinant plasmid can over-express the key regulator gene at the MAAs gene cluster site of the nostoc flagelliforme, so that the pseudocladostin synthesis capability of the nostoc flagelliforme is remarkably improved. The recombinant plasmid is transformed into nostoc flagelliforme to obtain a nostoc flagelliforme mutant, and after the nostoc flagelliforme mutant is cultured for 15 days, the content of cladosporin is 2.4 times that of wild nostoc flagelliforme.

Described herein are compositions and methods for treatment of haploinsufficiency disorders by mRNA regulation. For example, provided herein are fusion proteins that include an RNA effector protein that targets mRNA(s) of an active allele of a gene associated with a haploinsufficiency disorder; and a regulon moiety that stimulates and / or stabilizes the mRNA(s).

This invention relates to the field of genetic engineering technology, specifically to a recombinant plasmid, its construction method, and its application in enhancing the synthesis of pseudocladocerin from Nostoc flagelliforme. The recombinant plasmid includes a vector plasmid, and sgRNA target sequences, HR homologous sequences, psbA promoter sequences, and other components linked to the vector plasmid. ScyR Regulatory genes. This recombinant plasmid can be used in black moss. MAAs Overexpression of key regulatory genes at gene cluster sites significantly enhanced the pseudocranophane synthesis capacity of Nostoc commune. The Nostoc mutant obtained by transforming this recombinant plasmid into Nostoc commune exhibited a pseudocranophane content 2.4 times higher than that of wild-type Nostoc commune after 15 days of culture.

The present disclosure provides inducible constructs comprising a transcription initiator and / or a transcription regulator. These constructs can be used to drive gene expression in response to a particular cellular state, such as in the context of antigen stimulation. In some embodiments, these constructs are integrated as part of a regulatory circuit, useful for controlling expression and regulation of cells expressing engineered receptors.

Provided herein are compositions comprising small genes containing splice modulator binding sequences for tunable gene expression, as well as systems and methods of use thereof.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

Disclosed is a technique for constructing optogenetic amplifier and inverter circuits utilizing transcriptional activator / repressor pairs, in which expression of the transcriptional activator or repressor, respectively, is controlled by light-controlled transcription factors. This system is demonstrated utilizing the quinic acid regulon system from Neurospora crassa, or Q System, a transcriptional activator / repressor system. This is also demonstrated utilizing the galactose regulon from Saccharomyces cerevisiae, or GAL System. Such optogenetic amplifier circuits enable multi-phase microbial fermentations, in which different light schedules are applied in each phase to dynamically control different metabolic pathways for the production of proteins, fuels or chemicals. The orthogonal nature of the Q and GAL systems enable the co-expression of amplifier and inverter circuits to simultaneously amplify and invert the response of light-controlled transcriptional controls over different sets of genes in the same cell.

Provided is a method for increasing the productivity of secondary metabolites such as antibiotics in a microorganism. In particular, provided is a method to improve the productivity of secondary metabolites in a microorganism by inactivating or reducing the expression of FadR transcription regulator and Srb RNA binding protein of said microorganism.

Methods for determining regulon enrichment in gene expression signatures are disclosed herein. An example method can include obtaining a set of transcriptional targets of a regulon. The method can include obtaining a gene expression signature by comparing a gene expression profile of a test sample to gene expression profiles of a plurality of samples representing control phenotypes. The method can include calculating a regulon enrichment score for each regulon in the gene expression signature. The method can including determining whether a number of control samples in the control phenotypes is above a predetermined threshold to support evaluation of statistical significance using permutation analysis. The method can include, in response to determining that the number of control samples is above the predetermined threshold, calculating a significance value by comparing each regulon enrichment score to a null model.

The invention belongs to the technical field of reproductive medicine and molecular biology, and particularly discloses RBM24 serving as a therapeutic target for female low fertility and application of the RBM24 serving as the therapeutic target, the key effect of the RBM24 in ovarian granular cells and endometrial stem cells is disclosed for the first time, regulation and control of RBM24 expression or interaction of the RBM24 and Smad2mRNA are found, and the therapeutic target is used for treating female low fertility. The traditional Chinese medicine composition can promote proliferation of granular cells, maintain normal development of follicles, regulate regeneration and repair of endometrial stem cells and improve endometrial receptivity, and the technical scheme provided by the invention provides a new means and scheme for development, prevention and treatment of medicines for female low fertility.